We are experts in antimicrobial drug discovery, exploring innovative ways to address the global challenge of emerging bacterial drug resistance. Our research enhances discovery efforts across the pipeline—from early target validation to in-depth characterization of novel antimicrobial substances. We develop fast and predictive high-throughput screening (HTS) tools, such as bacterial bioreporters, and employ both target-based and cell-based strategies in our screening campaigns. We also work with advanced phenotypic cell models and investigate the effects of new compounds on host-pathogen interactions using multi-species co-cultures and in vivo experiments. Through collaborations, our expertise in screening technologies and assay development is applied to other therapeutic areas as well. We place special emphasis on natural products (NPs) and NP-inspired synthetic compounds to promote their integration into HTS workflows.
We belong to the Drug Research Program and the Division of Pharmaceutical Biosciences at the Faculty of Pharmacy. We are also hosting the DDCB Screening Unit, which provides researchers access to screening instrumentation as well as consultation in matters such as compound libraries, screening assay development and quality control relevant for screening campaigns. This unit belongs to the Drug Discovery and Chemical Biology network, and is a HiLIFE infrastructure facility, and EU-OPENSCREEN partner site. Please visit the DDCB Pharmacy website for further information.